Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CHE Stock Forecast 2025-2026
$555.74
Current Price
$8.12B
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CHE Price Targets
+27.4%
To High Target of $708.00
+21.3%
To Median Target of $674.00
+17.0%
To Low Target of $650.00
CHE Price Momentum
-1.4%
1 Week Change
-8.2%
1 Month Change
-0.8%
1 Year Change
+4.9%
Year-to-Date Change
-10.9%
From 52W High of $623.61
+8.5%
From 52W Low of $512.12
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Chemed (CHE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CHE and similar high-potential opportunities.
Latest CHE Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CHE has a bullish consensus with a median price target of $674.00 (ranging from $650.00 to $708.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $555.74, the median forecast implies a 21.3% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Michael Wiederhorn at Oppenheimer, suggesting a 17.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CHE Analyst Ratings
3
Buy
0
Hold
0
Sell
CHE Price Target Range
Low
$650.00
Average
$674.00
High
$708.00
Current: $555.74
Latest CHE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CHE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $667.00 |
| Nov 5, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $633.00 |
| May 21, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $697.00 |
| Mar 4, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $712.00 |
| Feb 29, 2024 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $650.00 |
| Jan 17, 2024 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $625.00 |
| Oct 30, 2023 | RBC Capital | Ben Hendrix | Outperform | Maintains | $604.00 |
| Jul 31, 2023 | RBC Capital | Ben Hendrix | Outperform | Maintains | $576.00 |
| Jul 27, 2023 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $590.00 |
| May 1, 2023 | RBC Capital | Ben Hendrix | Outperform | Maintains | $610.00 |
| Apr 28, 2023 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $610.00 |
| Feb 27, 2023 | RBC Capital | Ben Hendrix | Outperform | Maintains | $587.00 |
| Nov 3, 2022 | RBC Capital | Ben Hendrix | Outperform | Maintains | $545.00 |
| Aug 1, 2022 | RBC Capital | Ben Hendrix | Outperform | Maintains | $541.00 |
| Apr 28, 2022 | RBC Capital | Ben Hendrix | Outperform | Maintains | $592.00 |
| Mar 4, 2022 | RBC Capital | Frank Morgan | Outperform | Maintains | $579.00 |
| Jul 29, 2021 | RBC Capital | Frank Morgan | Outperform | Maintains | $609.00 |
| Feb 25, 2021 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $580.00 |
| Mar 11, 2020 | RBC Capital | Frank Morgan | Outperform | Upgrade | $535.00 |
| Feb 19, 2020 | Oppenheimer | Outperform | Maintains | $535.00 |
Chemed Corporation (CHE) Competitors
The following stocks are similar to Chemed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Chemed Corporation (CHE) Financial Data
Chemed Corporation has a market capitalization of $8.12B with a P/E ratio of 27.1x. The company generates $2.49B in trailing twelve-month revenue with a 12.4% profit margin.
Revenue growth is +9.8% quarter-over-quarter, while maintaining an operating margin of +14.6% and return on equity of +26.1%.
Valuation Metrics
Market Cap
$8.12B
Enterprise Value
$8.10B
P/E Ratio
27.1x
PEG Ratio
22.3x
Price/Sales
3.3x
Growth & Margins
Revenue Growth (YoY)
+9.8%
Gross Margin
+36.6%
Operating Margin
+14.6%
Net Margin
+12.4%
EPS Growth
+10.4%
Financial Health
Cash/Price Ratio
+2.1%
Current Ratio
1.7x
Debt/Equity
12.3x
ROE
+26.1%
ROA
+14.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Chemed Corporation (CHE) Business Model
About Chemed Corporation
What They Do
Provides hospice care and plumbing services.
Business Model
The company operates primarily through two segments: VITAS Healthcare, a leading hospice care provider, and Roto-Rooter, which offers plumbing and drain cleaning services. Revenue is generated from providing end-of-life care and essential home maintenance services, capitalizing on the critical nature of both healthcare and residential services.
Additional Information
Chemed Corporation's strategic diversification across healthcare and service sectors enhances its stability and resilience, allowing it to thrive in various economic conditions. Its commitment to serving terminally ill patients and maintaining residential properties positions it as a vital player in both industries.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
15,695
CEO
Mr. Kevin J. McNamara
Country
United States
IPO Year
1973
Website
www.chemed.comChemed Corporation (CHE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
CHE Stock Falls Despite Q1 Earnings & Revenue Beat, Gross Margin Declines
Chemed delivers first-quarter top-line growth across two of its segments, VITAS and Roto-Rooter.
Apr 25, 2025
By Zacks Equity Research
Analyst Blog
Chemed (CHE) Surpasses Q1 Earnings and Revenue Estimates
Chemed (CHE) delivered earnings and revenue surprises of 0.54% and 1.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Apr 23, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Chemed Corporation (NYSE: CHE) will hold its Q1 2025 Earnings Conference Call on April 24, 2025, at 10:00 AM ET, featuring key executives and analysts.
Why It Matters
The earnings call provides insights into Chemed's financial performance and future outlook, impacting stock valuation and investment decisions. Market reactions may follow based on results shared.
Source: Seeking Alpha
Market Sentiment:
Neutral
Chemed Reports First-Quarter 2025 Results
5 days ago
Quick Summary
Chemed Corporation (NYSE: CHE) reported a 9% revenue increase for Q1 2025, driven by its VITAS Healthcare and Roto-Rooter divisions.
Why It Matters
Chemed Corporation's revenue growth signals strong performance in both healthcare and plumbing sectors, indicating potential for continued profitability and stability, attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Chemed (CHE) reported quarterly earnings of $5.63 per share, surpassing the Zacks Consensus Estimate of $5.60 and up from $5.20 per share year-over-year.
Why It Matters
Chemed's earnings beat estimates and show year-over-year growth, indicating strong financial performance, which could boost investor confidence and drive stock prices higher.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Chemed reports first-quarter revenue growth in its VITAS and Roto-Rooter segments.
Why It Matters
Chemed's growth in VITAS and Roto-Rooter suggests strong demand and operational efficiency, potentially boosting profitability and investor confidence in the company's future performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in Medical - Outpatient and Home Healthcare stocks are considering Option Care (OPCH) and Chemed (CHE) for potential undervaluation.
Why It Matters
The comparison of Option Care and Chemed highlights potential investment opportunities in the outpatient and home healthcare sector, signaling interest in undervalued stocks for strategic portfolio decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Chemed To Report First-Quarter 2025 Earnings April 23, Related Conference Call To Be Held On April 24
27 days ago
Quick Summary
Chemed Corporation (NYSE: CHE) will release Q1 2025 financial results on April 23, 2025, and will host a conference call on April 24 at 10 a.m. ET to discuss the results and business update.
Why It Matters
Chemed Corporation's upcoming financial results and conference call could impact stock performance, providing insights into company health and future projections, influencing investor decisions.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CHE Stock
What is Chemed Corporation's (CHE) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Chemed Corporation (CHE) has a median price target of $674.00. The highest price target is $708.00 and the lowest is $650.00.
Is CHE stock a good investment in 2025?
According to current analyst ratings, CHE has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $555.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CHE stock?
Wall Street analysts predict CHE stock could reach $674.00 in the next 12 months. This represents a 21.3% increase from the current price of $555.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Chemed Corporation's business model?
The company operates primarily through two segments: VITAS Healthcare, a leading hospice care provider, and Roto-Rooter, which offers plumbing and drain cleaning services. Revenue is generated from providing end-of-life care and essential home maintenance services, capitalizing on the critical nature of both healthcare and residential services.
What is the highest forecasted price for CHE Chemed Corporation?
The highest price target for CHE is $708.00 from at , which represents a 27.4% increase from the current price of $555.74.
What is the lowest forecasted price for CHE Chemed Corporation?
The lowest price target for CHE is $650.00 from Michael Wiederhorn at Oppenheimer, which represents a 17.0% increase from the current price of $555.74.
What is the overall CHE consensus from analysts for Chemed Corporation?
The overall analyst consensus for CHE is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $674.00.
How accurate are CHE stock price projections?
Stock price projections, including those for Chemed Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 12:37 PM UTC